Data from Allergy - Curated by EPG Health - Date available 03 November 2003
Availability
Pay for access, or by subscription
Original date published
3 November 2003
Original format
Epub ahead of print
Even since the late 19th century, a relationship has been suspected between upper airway disease and the subsequent development or aggravation of asthma symptoms. To date, it has been generally accepted that pathologic conditions of the upper airways, e.g. allergic rhinitis, chronic sinusitis and nasal polyposis, may influence the lower airways. However, the mechanisms underlying this relationship were, for a long time, poorly understood. Recently, evidence has been accumulating which indicates a systemic connection as one of the responsible mechanisms in nasobronchial crosstalk. In this review, the pathophysiologic and immunologic aspects of the interaction between upper and lower airways will be discussed.
Data sources
Read abstract on library site Access full article
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Moderate to severe asthma
Access the comprehensive Learning Zone for moderate to severe asthma. Containing details about pathophysiology, a complete overview of asthma and daily reports from ERS Congress 2019.
EADV 2018 Highlights
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Related Content
EAACI Congress 2018
View resources from this year’s EAACI Congress which took place in Munich, Germany from 26–30 May 2018, and is the world's largest allergy, asthma and clinical immunology meeting.
Added 1 year ago
AAAAI/WAO 2018: joint allergy, immunology and asthma congress begins today in Florida
The 2018 AAAAI (American Academy of Allergy, Asthma & Immunology) and WAO (World Allergy Organization) congress begins today.
Added 1 year ago
FDA approves Tuzistra XR (codeine polistirex and chlorpheniramine polistirex)for Chronic Cough- Vernalis
The FDA has approved the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension,...
Added 4 years ago
FDA grants 510(k) approval for Propeller platform for use with Ellipta inhaler for asthma and COPD. -Propeller Health + GSK
Propeller Health, the leading digital solution for respiratory medicine, announced 510(k) clearance to market its Propeller platform for use with...
Added 3 years ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.